{"id":6351,"date":"2025-08-12T07:00:00","date_gmt":"2025-08-12T07:00:00","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=rkd-news&#038;p=6351"},"modified":"2025-10-14T13:02:50","modified_gmt":"2025-10-14T13:02:50","slug":"igan-sparsentan-concomitant-use","status":"publish","type":"rkd-news","link":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/","title":{"rendered":"Sparsentan in IgAN: Spotlight on Phase 2 and OLE Clinical Trial Results Evaluating Concomitant Use With SGLT2i"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n    <img decoding=\"async\" width=\"1921\" height=\"1081\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle.webp\" class=\"a-img a-img--right h-full\" alt=\"Hero Section Background Image\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle.webp 1921w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle-290x163.webp 290w\" sizes=\"auto, (max-width: 1921px) 100vw, 1921px\" \/>    <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">Sparsentan in IgAN: Spotlight on Phase 2 and OLE Clinical Trial Results Evaluating Concomitant Use With SGLT2i<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\r\n\t<section style=\"padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;margin-top:calc(-120px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\"><\/i> Published on August 12, 2025\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics: <\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\n\t\t<div class=\"info-block-box\">\n\t\t\t\n\t\t\t\t\t<\/div>\n\n\t\t\n\t\t<div class=\"info-block-share\">Share:\n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Figan-sparsentan-concomitant-use%2F&#038;text=Sparsentan+in+IgAN%3A+Spotlight+on+Phase+2+and+OLE+Clinical+Trial+Results+Evaluating+Concomitant+Use+With+SGLT2i\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Figan-sparsentan-concomitant-use%2F&#038;title=Sparsentan+in+IgAN%3A+Spotlight+on+Phase+2+and+OLE+Clinical+Trial+Results+Evaluating+Concomitant+Use+With+SGLT2i\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Figan-sparsentan-concomitant-use%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=Sparsentan%20in%20IgAN%3A%20Spotlight%20on%20Phase%202%20and%20OLE%20Clinical%20Trial%20Results%20Evaluating%20Concomitant%20Use%20With%20SGLT2i&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Frare-kidney-disease-news%2Figan-sparsentan-concomitant-use%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div class=\"modal modal-request-copy\" style=\"display: none;\" id=\"modal-request-copy\">\n\t<div class=\"modal__backdrop\">\n\t\t<div class=\"modal__card\">\n\t\t\t<button class=\"modal__close btn-close\" aria-label=\"Close modal\">&times;<\/button>\n\t\t\t<h4 class=\"has-heading-3-font-size\">Request a copy<\/h4>\n\t\t\t\n<div class=\"wpcf7 no-js\" id=\"wpcf7-f2317-o1\" lang=\"en-US\" dir=\"ltr\" data-wpcf7-id=\"2317\">\n<div class=\"screen-reader-response\"><p role=\"status\" aria-live=\"polite\" aria-atomic=\"true\"><\/p> <ul><\/ul><\/div>\n<form action=\"\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/6351#wpcf7-f2317-o1\" method=\"post\" class=\"wpcf7-form init wpcf7-acceptance-as-validation\" aria-label=\"Contact form\" novalidate=\"novalidate\" data-status=\"init\">\n<fieldset class=\"hidden-fields-container\"><input type=\"hidden\" name=\"_wpcf7\" value=\"2317\" \/><input type=\"hidden\" name=\"_wpcf7_version\" value=\"6.1.1\" \/><input type=\"hidden\" name=\"_wpcf7_locale\" value=\"en_US\" \/><input type=\"hidden\" name=\"_wpcf7_unit_tag\" value=\"wpcf7-f2317-o1\" \/><input type=\"hidden\" name=\"_wpcf7_container_post\" value=\"0\" \/><input type=\"hidden\" name=\"_wpcf7_posted_data_hash\" value=\"\" \/>\n<\/fieldset>\n<div class=\"cf7-fields-wrapper\">\n  <div class=\"form-two-cols\">\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-first-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-first-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"First Name*\" value=\"\" type=\"text\" name=\"request-first-name\" \/><\/span>\n    <\/div>\n    <div class=\"form-group\">\n      <span class=\"wpcf7-form-control-wrap\" data-name=\"request-last-name\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" id=\"request-last-name\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Last Name*\" value=\"\" type=\"text\" name=\"request-last-name\" \/><\/span>\n    <\/div>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-your-email\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-email wpcf7-validates-as-required wpcf7-text wpcf7-validates-as-email\" id=\"request-your-email\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Email*\" value=\"\" type=\"email\" name=\"request-your-email\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-title\"><input size=\"40\" maxlength=\"400\" class=\"wpcf7-form-control wpcf7-text wpcf7-validates-as-required\" aria-required=\"true\" aria-invalid=\"false\" placeholder=\"Title*\" value=\"\" type=\"text\" name=\"request-title\" \/><\/span>\n  <\/div>\n  <div class=\"form-group\">\n    <span class=\"wpcf7-form-control-wrap\" data-name=\"request-agree\"><span class=\"wpcf7-form-control wpcf7-acceptance\"><span class=\"wpcf7-list-item\"><label><input type=\"checkbox\" name=\"request-agree\" value=\"1\" class=\"required\" id=\"request-agree\" aria-invalid=\"false\" \/><span class=\"wpcf7-list-item-label\">All personal data will be processed by or on behalf of Travere to provide access to company information and to respond to requests. Travere will retain personal data only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal data is private and will not disseminate it to third parties who are not providing services to Travere. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\">Travere privacy policies<\/a>.<\/span><\/label><\/span><\/span><\/span>\n  <\/div>\n  <div class=\"form-group text-right\">\n    <input class=\"wpcf7-form-control wpcf7-submit has-spinner btn\" id=\"request-submit\" type=\"submit\" value=\"Yes, continue\" \/>\n  <\/div>\n<\/div><div class=\"wpcf7-response-output\" aria-hidden=\"true\"><\/div>\n<\/form>\n<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div> <\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(30px * var(--scale));padding-right:0px;padding-bottom:0px;padding-left:0px;\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">In this issue we: <\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li><a href=\"#h-the-iga-nephropathy-treatment-paradigm-is-evolving-with-hcps-exploring-earlier-dual-targeted-treatment-options-in-iga-nephropathy-1-5\"><strong>Discuss<\/strong> the <strong>evolving<\/strong> IgA nephropathy <strong>treatment paradigm<\/strong><\/a><\/li>\n<li><a href=\"#h-clinical-data-support-the-role-of-sparsentan-as-a-therapeutic-option-in-iga-nephropathy-8-9\"><strong>Highlight clinical data<\/strong> that support <strong>sparsentan\u2028<\/strong>as a <strong>foundational therapy<\/strong> in IgA nephropathy<\/a><\/li>\n<li><a href=\"#h-new-phase-2-spartacus-data-presented-at-era-2025-reported-data-on-the-concomitant-use-of-sparsentan-with-a-sglt2i-4\"><strong>Share<\/strong> Phase 2 SPARTACUS, Phase 3 PROTECT Open Label Extension (OLE), and <strong>real-world data<\/strong> evaluating the <strong>concomitant use of sparsentan<\/strong> and sodium-glucose cotransporter-2 inhibitors (<strong>SGLT2i<\/strong>)<\/a><\/li>\n<\/ul>\n<p><a name=\"video\"><\/a><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"event-video\" id=\"video\">\n\t\t\t<p class=\"has-heading-3-font-size\">Welcome by Professor J\u00f6rg Latus<\/p>\n\t\t\n\t<a href=\"#\" class=\"event-video--img\" style=\"background-image: url('https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1455-Travere-ERA-Newsletter-KOL-video-V01-00-20250626_Thumbnail-min-scaled.webp');\">\n\t\t<span class=\"icon2-play\" aria-hidden=\"true\"><\/span>\n\t<\/a>\n\t\n\t<div class=\"event-video--vimeo\"><\/div>\n\t\n\t<\/div>\n\n<script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script>\n<script>\n\tdocument.addEventListener(\"DOMContentLoaded\", function() {\n\t\tconst imgLink = document.querySelector(\".event-video--img\");\n\t\tconst vimeoDiv = document.querySelector(\".event-video--vimeo\");\n\t\tlet iframeExists = false;\n\t\tlet player;\n\n\t\timgLink.addEventListener(\"click\", function(event) {\n\t\t\tevent.preventDefault();\n\n\t\t\tif (!iframeExists) {\n\t\t\t\tconst iframe = document.createElement(\"iframe\");\n\t\t\t\tiframe.src = \"https:\/\/player.vimeo.com\/video\/1108179974\";\n\t\t\t\tiframe.frameBorder = \"0\";\n\t\t\t\tiframe.allow = \"autoplay; fullscreen\";\n\t\t\t\tiframe.allowFullscreen = true;\n\t\t\t\tvimeoDiv.appendChild(iframe);\n\t\t\t\t\n\t\t\t\tplayer = new Vimeo.Player(iframe);\n\t\t\t\tplayer.play();\n\t\t\t\tiframeExists = true;\n\t\t\t}\n\n\t\t\tvimeoDiv.style.display = \"block\";\n\t\t\timgLink.style.display = \"none\";\n\t\t});\n\n\t\tvimeoDiv.addEventListener(\"click\", function() {\n\t\t\tconst iframe = vimeoDiv.querySelector(\"iframe\");\n\t\t\tiframe.contentWindow.postMessage('{\"method\":\"play\"}', 'https:\/\/player.vimeo.com\/video\/1108179974');\n\t\t});\n\t});\n<\/script>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-the-iga-nephropathy-treatment-paradigm-is-evolving-with-hcps-exploring-earlier-dual-targeted-treatment-options-in-iga-nephropathy-1-5\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">The IgA nephropathy treatment paradigm is evolving with HCPs exploring earlier, dual-targeted treatment options in IgA nephropathy<sup>1-5<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Data from the <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/long-term-outcomes-in-iga-nephropathy\/\" target=\"_blank\" rel=\"noopener\">RaDaR study<\/a> have encouraged the nephrology community to strive towards earlier diagnoses, and further reduction of proteinuria and preservation of kidney function.<sup>6<\/sup> These goals continue to shape treatment decisions and have contributed to a growing focus on dual-targeted strategies, underscoring the importance of foundational therapy early in the disease course.<sup>1-5,7<\/sup><\/p>\n<p>Additionally, managing episodic immunosuppression also remains a consideration for patients who are at high-risk for disease progression.<sup>7<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Emerging treatment targets (0.3-0.5 g\/g UPCR and eGFR slope &lt;1 mL\/min\/1.73m<sup>2<\/sup>\/year) are supported by clinical trial and real world data.<sup>1-5,7<\/sup> The combination of well-tolerated therapies to potentially reduce proteinuria and preserve kidney function can include, but are not limited to<sup>1-5,7<\/sup>:<\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul style=\"padding-left:calc(50px * var(--scale))\" class=\"wp-block-list\">\n<li>A potential DEARA-based combination: Sparsentan combined with an SGLT2i<\/li>\n\n\n\n<li>A stepwise approach using separate agents: Renal angiotensin system inhibitors (RASi) with or without endothelin type A receptor (ET<sub>A<\/sub>R) antagonists and\/or SGLT2i<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Episodic immune suppression (IST) may also be used in tandem with these treatment combinations when necessary.<sup>7<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1214\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-300x142.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-1024x486.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-768x364.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-1536x729.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-2048x971.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Future-IgAN-Treatment-Landscape-290x138.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p>Figure. IgA nephropathy evolving treatment paradigm<sup>1,7<\/sup><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-clinical-data-support-the-role-of-sparsentan-as-a-therapeutic-option-in-iga-nephropathy-8-9\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Clinical data support the role of sparsentan as a therapeutic option in IgA nephropathy<sup>8,9<\/sup><\/mark><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p><a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protect-2-year-results-sparsentan-vs-irbesartan-iga-nephropathy\/\" target=\"_blank\" rel=\"noopener\">Two-year data<\/a> and <a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/\" target=\"_blank\" rel=\"noopener\"><em>post hoc<\/em> analyses<\/a> from the Phase 3 PROTECT trial have indicated that sparsentan was associated with a <a href=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/\" target=\"_blank\" rel=\"noopener\">greater reduction in proteinuria<\/a> and <a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-proteinuria-remission-egfr\/\" target=\"_blank\" rel=\"noopener\">preservation of kidney function<\/a> compared to maximum labeled dose irbesartan.<sup>1,8<\/sup> Sparsentan was also well tolerated with a safety profile comparable to irbesartan.<sup>8,9<\/sup> These data suggest the potential for sparsentan as a long-term therapeutic option for IgA nephropathy.<sup>1,8<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-new-phase-2-spartacus-data-presented-at-era-2025-reported-data-on-the-concomitant-use-of-sparsentan-with-a-sglt2i-4\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">New Phase 2 SPARTACUS data<\/mark><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"> <a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/era-congress-2025\/\" target=\"_blank\" rel=\"noreferrer noopener\"><span class=\"text-decoration-underline\">presented at ERA 2025<\/span><\/a><\/mark><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"> reported data on the concomitant use of sparsentan with a SGLT2i<sup>4<\/sup><\/mark><\/span><\/h2>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>SPARTACUS was an exploratory, open-label, single arm, multicenter study that assessed the safety and efficacy of replacing RASi with sparsentan in adults with IgA nephropathy (N=48) receiving stable SGLT2i therapy.<sup>4<\/sup><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Replacing RASi with sparsentan in patients receiving stable SGLT2i treatment resulted in rapid and sustained reductions in proteinuria, with urine protein-creatinine ratio (UPCR) percentage decreasing by approximately 45% from baseline over 24 weeks.<sup>4<\/sup><\/p>\n\n\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1440\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-2048x1152.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-at-Each-Visit-290x163.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p>Figure. SPARTACUS: Change in UPCR at each visit<sup>4<\/sup><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Additionally, nearly one third of patients achieved urine albumincreatinine ratio (UACR) &lt;0.2 g\/g.<sup>4<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1469\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-300x172.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-1024x588.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-768x441.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-1536x881.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-2048x1175.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Patients-Achieving-UACR-Reduction-290x166.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p>Figure. SPARTACUS: Percent of patients achieving UACR reduction endpoints at Week 24<sup>4<\/sup><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Notably, estimated glomerular filtration rate (eGFR) remained relatively stable and blood pressure initially slightly decreased throughout the 24-week study period.<sup>4<\/sup><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Concomitant use of sparsentan with an SGLT2i was generally well tolerated, with no unexpected safety signals reported.<sup>4<\/sup><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>Most common adverse events included: hypotension (n=7), headache (n=4), edema (n=4), peripheral edema (n=4), upper respiratory tract infection (n=4), and dizziness (n=3)<sup>4<\/sup><\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-previous-data-presented-at-asn-2024-from-the-ongoing-protect-ole-study-report-on-the-safety-and-efficacy-of-stable-sparsentan-with-the-addition-of-an-sglt2i-2\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Previous data presented at ASN 2024 from the ongoing PROTECT OLE study report on the <\/mark><a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-iga-nephropathy-protect-ole\/\" target=\"_blank\" rel=\"noreferrer noopener\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span class=\"text-decoration-underline\">safety and efficacy of stable sparsentan with the addition of an SGLT2i<\/span><\/mark><\/a><sup><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">2<\/mark><\/sup><\/span><\/h2>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>PROTECT OLE findings also suggested further reduction in proteinuria and relatively stable eGFR levels.<sup>2<\/sup> The combination was found to be generally well tolerated with no new safety signals identified.<sup>2<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1556\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-300x182.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-1024x622.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-768x467.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-1536x933.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-2048x1245.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/UPCR-over-time-with-SGLT2i-290x176.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p>Figure. PROTECT OLE: UPCR over time with SGLT2i added to stable sparsentan treatment<sup>2<\/sup><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Together, data from SPARTACUS and PROTECT OLE clinical trials suggest reductions in proteinuria occurs when replacing RASi with sparsentan, and when sparsentan is used in combination with SGLT2i.<sup>2,4<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-findings-from-real-world-studies-also-report-on-the-potential-for-combined-use-of-sparsentan-and-sglt2i-3-5\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Findings from real-world studies also report on the potential for combined use of sparsentan and SGLT2i<sup>3,5<\/sup><\/mark><\/span><\/h2>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Data from a <a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/sparsentan-sglt2i-combination-igan-case-series\/\" target=\"_blank\" rel=\"noreferrer noopener\">real-world case series<\/a> and cohort study suggested additive proteinuric benefit of concomitant use of sparsentan with SGLT2i in patients with IgA nephropathy, and the combination was generally well tolerated.<sup>3,5<\/sup><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>In a real-world case series presented at ASN 2024, four patients with IgA nephropathy, who had been treated with steroid\/immunosuppressive treatment (alone [n=2] or in combination with a RASi [n=1]), or RASi alone (n=1), were transitioned to concurrent treatment with sparsentan and SGLT2i, and were followed for a period ranging from 3-10 months.<sup>5<\/sup><\/p>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>During the study period, concurrent use of sparsentan and SGLT2i led to reductions in proteinuria, with observed decreases in UPCR ranging from -38% after 3 months of concurrent use to -82% after 10 months.<sup>5<\/sup> Two patients also achieved UPCR &lt;0.5 g\/g at any time during sparsentan treatment.<sup>5<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-scaled.webp\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1681\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-300x197.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-1024x672.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-768x504.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-1536x1008.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-2048x1344.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Change-in-UPCR-over-10-months-290x190.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p>Figure. Real-world data: Change in UPCR over 10 Months<sup>5<\/sup><\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<p>Notably, patients experienced further reductions in proteinuria (n=3) and albuminuria (n=1) compared with their prior treatments.<sup>5<\/sup> These improvements were observed regardless of patients\u2019 baseline proteinuria levels or eGFR.<sup>5<\/sup> Renal function and blood pressure also remained relatively stable throughout the 3-10 month follow-up period.<sup>5<\/sup> No treatment discontinuations occurred due to safety concerns.<sup>5<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-scaled.webp\" >\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1056\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-scaled.webp\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-300x124.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-1024x422.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-768x317.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-1536x634.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-2048x845.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Data-section-header-290x120.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p>Additional real-world data published from a study across several German clinics evaluated the dual therapy approach of sparsentan in patients already receiving stable SGLT2i therapy (N=23).<sup>3<\/sup><\/p>\n<p>After initiation of sparsentan, UPCR decreased to a median of 0.85 (0.42-1.15) g\/g at the 2-week follow-up, corresponding to a relative reduction in proteinuria of 44% from baseline.<sup>3<\/sup><\/p>\n<p>UPCR continued to decline further with median UPCR reaching 0.60 (0.32-0.82) g\/g after 14 weeks, resulting in a relative reduction of up to 62%.<sup>3<\/sup><\/p>\n<p>Similar reductions were observed with UACR.<sup>3<\/sup><\/p>\n<p>In the authors\u2019 analysis, these reductions in proteinuria and albuminuria were noted to be comparable to the effects observed in the PROTECT trial.<sup>3<\/sup><\/p>\n<p>Similar to previous findings, the combination of sparsentan and SGLT2i was well tolerated, with no drug-related serious adverse events reported.<sup>3<\/sup><\/p>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-gray-300-color has-alpha-channel-opacity has-gray-300-background-color has-background\"\/>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>As healthcare professionals navigate an evolving treatment landscape, clinical trial and real-world data offer important considerations for IgA nephropathy management.<sup>2-5<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading has-text-align-center has-heading-4-font-size has-ocean-blue-color has-text-color has-link-color wp-elements-c898f5d372f7caff4b4f01ee96bf2edb\" id=\"h-related-content\" style=\"margin-bottom:calc(30px * var(--scale))\"><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">Related Content<\/mark><\/strong><\/h5>\n\n\n<div id=\"rkd-news\" class=\"rkd-news\">\n\t\t\t<div class=\"rkd-news-list\">\n\t\t\t\t\t\t\t\t<div class=\"m-card\">\n\t\t\t\t\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/\" aria-label=\"View Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy\">\n\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1921\" height=\"1081\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp\" class=\"a-img wp-post-image\" alt=\"Engaging Patients for Better Outcomes: Informed Care for IgA Nephropathy\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029.webp 1921w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/MCE1307-Travere-MA-Website-Header-Innovation-V00-01-20241029-290x163.webp 290w\" sizes=\"auto, (max-width: 1921px) 100vw, 1921px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<div class=\"m-card__info\">\n\t\t\t\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag a-tag--purple\">Nephrology<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t\t\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\"><\/p>\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">Issue 1<\/p>\n\t\t\t\t\t\t\t\t<h4 class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\t\t\t\t\tEngaging Patients for Better Outcomes: Informed Care for IgA Nephropathy\t\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\"><em>Access IgAN patient education resources, learn more about how IgAN develops, and explore advancements in IgAN care.<\/em><\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/informed-healthcare-for-patients-with-igan\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Learn more\">\n\t\t\t\t\t\t\t\t<span>Learn more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<div class=\"m-card\">\n\t\t\t\t\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/\" aria-label=\"View ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy\">\n\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png\" class=\"a-img wp-post-image\" alt=\"ASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/12\/graph-magnifying-glass_header-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<div class=\"m-card__info\">\n\t\t\t\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag a-tag--purple\">Nephrology<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t\t\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\"><\/p>\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">Issue 1<\/p>\n\t\t\t\t\t\t\t\t<h4 class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\t\t\t\t\tASN 2024 Spotlight: New Treatment Targets in IgA Nephropathy\t\t\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\"><em>Learn more about patients on sparsentan achieving updated proteinuria treatment goals outlined in the 2024 KDIGO draft guideline.<\/em><\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/asn-2024-spotlight-sparsentan-complete-remission\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Learn more\">\n\t\t\t\t\t\t\t\t<span>Learn more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<div class=\"rkd-more\">\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/?p=4687\" class=\"btn\">See more<\/a>\n\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<h5 class=\"wp-block-heading has-ocean-blue-color has-text-color has-link-color wp-elements-51cd0c4ef90fd47f09aee67a5374353a\" id=\"h-references\" style=\"margin-bottom:calc(30px * var(--scale))\"><strong>References<\/strong><\/h5>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">KDIGO Clinical Practice Guidelines for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Accessed 22 October 2024. <a href=\"https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf<\/a>.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kooienga I et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR PO851.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Schanz M et al. <em>Clin Kidney J.<\/em> 2025;18(1):sfae394.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Ayoub I et al. Presented at: European Renal Association 2025; June 4 7, 2025; Vienna, Austria.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Ravipati P et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR PO906.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Pitcher D et al. <em>Clin J Am Soc Nephrol.<\/em> 2023;18(6):727 738.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Barratt J et al. <em>Front Med (Lausanne).<\/em> 2024;11:1461879.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rovin BH et al. <em>Lancet<\/em>. 2023;402(10417):2077 2090.<\/li>\n\n\n\n<li class=\"has-small-font-size\">FILSPARI\u00ae (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc. 9\/2024.<\/li>\n<\/ol>\n<\/div>\n\n\n<p class=\"has-text-align-right has-small-font-size\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\">MA-SP-25-0108 | August 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":6381,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":""},"product":[78],"therapeutic_area":[97],"disease_area":[174],"study_registry":[247,198],"study_type":[],"resource_type":[208],"class_list":["post-6351","rkd-news","type-rkd-news","status-publish","has-post-thumbnail","hentry","product-spa","therapeutic_area-neph","disease_area-igan","study_registry-protect-ole","study_registry-spartacus","resource_type-newsletter"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rare Kidney Disease News | Evaluating Concomitant Use of Sparsentan With SGLT2i<\/title>\n<meta name=\"description\" content=\"Explore insights from the Phase 2 SPARTACUS trial, PROTECTOLE, and real-world data evaluating use of sparsentan withSGLT2i in IgAN\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sparsentan in IgAN: Spotlight on Phase 2 and OLE Clinical Trial Results Evaluating Concomitant Use With SGLT2i\" \/>\n<meta property=\"og:description\" content=\"Explore insights from the Phase 2 SPARTACUS trial, PROTECTOLE, and real-world data evaluating use of sparsentan withSGLT2i in IgAN\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T13:02:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1921\" \/>\n\t<meta property=\"og:image:height\" content=\"1081\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/igan-sparsentan-concomitant-use\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/igan-sparsentan-concomitant-use\\\/\",\"name\":\"Rare Kidney Disease News | Evaluating Concomitant Use of Sparsentan With SGLT2i\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/igan-sparsentan-concomitant-use\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/igan-sparsentan-concomitant-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Pills-Bottle.webp\",\"datePublished\":\"2025-08-12T07:00:00+00:00\",\"dateModified\":\"2025-10-14T13:02:50+00:00\",\"description\":\"Explore insights from the Phase 2 SPARTACUS trial, PROTECTOLE, and real-world data evaluating use of sparsentan withSGLT2i in IgAN\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/igan-sparsentan-concomitant-use\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/igan-sparsentan-concomitant-use\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/igan-sparsentan-concomitant-use\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Pills-Bottle.webp\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/Pills-Bottle.webp\",\"width\":1921,\"height\":1081},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/rare-kidney-disease-news\\\/igan-sparsentan-concomitant-use\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ERA 2025 IgAN Sparsentan Concomitant Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rare Kidney Disease News | Evaluating Concomitant Use of Sparsentan With SGLT2i","description":"Explore insights from the Phase 2 SPARTACUS trial, PROTECTOLE, and real-world data evaluating use of sparsentan withSGLT2i in IgAN","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Sparsentan in IgAN: Spotlight on Phase 2 and OLE Clinical Trial Results Evaluating Concomitant Use With SGLT2i","og_description":"Explore insights from the Phase 2 SPARTACUS trial, PROTECTOLE, and real-world data evaluating use of sparsentan withSGLT2i in IgAN","og_url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-14T13:02:50+00:00","og_image":[{"width":1921,"height":1081,"url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle.webp","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/","url":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/","name":"Rare Kidney Disease News | Evaluating Concomitant Use of Sparsentan With SGLT2i","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle.webp","datePublished":"2025-08-12T07:00:00+00:00","dateModified":"2025-10-14T13:02:50+00:00","description":"Explore insights from the Phase 2 SPARTACUS trial, PROTECTOLE, and real-world data evaluating use of sparsentan withSGLT2i in IgAN","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle.webp","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/Pills-Bottle.webp","width":1921,"height":1081},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/rare-kidney-disease-news\/igan-sparsentan-concomitant-use\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"ERA 2025 IgAN Sparsentan Concomitant Use"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 10:19:01","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"therapeutic_area","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news\/6351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/rkd-news"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/rkd-news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/6381"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=6351"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=6351"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=6351"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=6351"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=6351"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=6351"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=6351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}